New tuberculosis vaccines in India: Modelling the potential health and economic impacts of adolescent/adult vaccination with M72/AS01E and BCG-revaccination

Background India had an estimated 2.9 million tuberculosis cases and 506 thousand deaths in 2021. Novel vaccines effective in adolescents and adults could reduce this burden. M72/AS01E and BCG-revaccination have recently completed Phase IIb trials and estimates of their population-level impact are needed. We estimated the potential health and economic impact of M72/AS01E and BCG-revaccination in India and investigated the impact of variation in vaccine characteristics and delivery strategies. Methods We developed an age-stratified compartmental tuberculosis transmission model for India calibrated to country-specific epidemiology. We projected current trends to 2050 assuming no-new-vaccine introduction, and M72/AS01E and BCG-revaccination scenarios over 2025-2050 exploring uncertainty in product characteristics and implementation. We estimated reductions in tuberculosis cases and deaths by each scenario compared to no-new-vaccine introduction, as well as costs and cost-effectiveness from health-system and societal perspectives. Results M72/AS01E scenarios were predicted to avert 40% more tuberculosis cases and deaths by 2050 compared to BCG-revaccination scenarios. Cost-effectiveness ratios for M72/AS01E vaccines were around seven times higher than BCG-revaccination, but nearly all scenarios were cost-effective. The estimated average incremental cost was US$190 million for M72/AS01E and US$23 million for BCG-revaccination per year. Sources of uncertainty included whether M72/AS01E was efficacious in uninfected individuals at vaccination, and if BCG-revaccination could prevent disease. Conclusions M72/AS01E and BCG-revaccination could be impactful and cost-effective in India. However, there is great uncertainty in impact, especially with varying vaccine characteristics. Greater investment in vaccine development and delivery is needed to raise the probability of success.

[1]  M. Jit,et al.  The cost and cost-effectiveness of novel tuberculosis vaccines in low- and middle-income countries: A modeling study , 2023, PLoS medicine.

[2]  M. Jit,et al.  The potential impact of novel tuberculosis vaccine introduction on economic growth in low- and middle-income countries: A modeling study , 2022, medRxiv.

[3]  M. Jit,et al.  The potential impact of novel tuberculosis vaccines on health equity and financial protection in low-income and middle-income countries , 2022, BMJ Global Health.

[4]  K. Rajendran,et al.  Revisiting the Chingleput BCG vaccination trial for the impact of BCG revaccination on the incidence of tuberculosis disease , 2022, The Indian journal of medical research.

[5]  J. Seeley,et al.  Potential implementation strategies, acceptability, and feasibility of new and repurposed TB vaccines , 2022, PLOS global public health.

[6]  Richard G. White,et al.  The epidemiologic impact and cost-effectiveness of new tuberculosis vaccines on multidrug-resistant tuberculosis in India and China , 2021, BMC Medicine.

[7]  Richard G. White,et al.  New tuberculosis vaccines: advances in clinical development and modelling , 2020, Journal of internal medicine.

[8]  Richard G. White,et al.  Potential impact of tuberculosis vaccines in China, South Africa, and India , 2020, Science Translational Medicine.

[9]  Eun Sug Park,et al.  Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019 , 2020, Lancet.

[10]  L. Abu-Raddad,et al.  Epidemiological impact of targeted interventions for people with diabetes mellitus on tuberculosis transmission in India: Modelling based predictions. , 2019, Epidemics.

[11]  M. Demoitié,et al.  Final Analysis of a Trial of M72/AS01E Vaccine to Prevent Tuberculosis. , 2019, The New England journal of medicine.

[12]  James Lomas,et al.  Estimating health opportunity costs in low-income and middle-income countries: a novel approach and evidence from cross-country data , 2018, BMJ Global Health.

[13]  S. Self,et al.  Prevention of Infection with Mycobacterium tuberculosis by H4:IC31® Vaccination or BCG Revaccination in Adolescents , 2018, The New England journal of medicine.

[14]  Richard G. White,et al.  Impact of Targeted Tuberculosis Vaccination Among a Mining Population in South Africa: A Model-Based Study , 2017, American journal of epidemiology.

[15]  A. Culyer,et al.  The International Decision Support Initiative Reference Case for Economic Evaluation: An Aid to Thought. , 2016, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[16]  Richard G. White,et al.  Impact and cost-effectiveness of new tuberculosis vaccines in low- and middle-income countries , 2014, Proceedings of the National Academy of Sciences.

[17]  J. Sterne,et al.  Protection by BCG vaccine against tuberculosis: a systematic review of randomized controlled trials. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  B. Saxena,et al.  Indian Council of Medical Research ICMR Task Force Study on hormonal contraceptives , 1986 .